Experienced in Methicillin-Resistant Staphylococcus Aureus (MRSA)

Dr. Julia B. Garcia-Diaz

Infectious Disease
1514 Jefferson Hwy, 
New Orleans, LA 
Accepting New Patients
Experienced in Methicillin-Resistant Staphylococcus Aureus (MRSA)
1514 Jefferson Hwy, 
New Orleans, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julia Garcia-Diaz is an Infectious Disease provider in New Orleans, Louisiana. Dr. Garcia-Diaz is rated as an Experienced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). Her top areas of expertise are HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome. Dr. Garcia-Diaz is currently accepting new patients.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Methicillin-Resistant Staphylococcus Aureus (MRSA).

Specialties
Infectious Disease
Licenses
Internal Medicine in LA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1514 Jefferson Hwy, New Orleans, LA 70121

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age
A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age
Enrollment Status: Completed
Publish Date: March 04, 2025
Intervention Type: Combination product, Biological
Study Phase: Phase 3
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
Enrollment Status: Completed
Publish Date: November 13, 2024
Intervention Type: Other, Drug
Study Drugs: Ivermectin, Fluvoxamine, Fluticasone
Study Phase: Phase 3
A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections
A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Phase: Phase 2
Assessment of Cognitive Ability and the Intestinal Microbiome in Individuals With Liver Disease Before and After Investigational Microbiota Restoration Therapeutic
Assessment of Cognitive Ability and the Intestinal Microbiome in Individuals With Liver Disease Before and After Investigational Microbiota Restoration Therapeutic
Enrollment Status: Terminated
Publish Date: October 03, 2023
Intervention Type: Biological
Study Drug: RBX7455
Study Phase: Phase 2
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Infliximab, Abatacept, Remdesivir, Cenicriviroc
Study Phase: Phase 3
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19
Enrollment Status: Terminated
Publish Date: June 26, 2023
Intervention Type: Other, Drug, Biological
Study Drugs: Anti-CD14, Remdesivir
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: TJ003234
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
Enrollment Status: Terminated
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

38 Total Publications

Protocol for an international, multicentre, prospective, observational study of nosocomial pneumonia in intensive care units: the PneumoINSPIRE study.
Protocol for an international, multicentre, prospective, observational study of nosocomial pneumonia in intensive care units: the PneumoINSPIRE study.
Journal: Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine
Published: December 04, 2023
Similar Doctors
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. George T. Keshelava
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. George T. Keshelava
Infectious Disease
39 Starbrush Cir, 
Covington, LA 
 (34.7 miles away)
985-871-4155
Languages Spoken:
English
See accepted insurances
Accepting New Patients

George Keshelava is an Infectious Disease provider in Covington, Louisiana. Dr. Keshelava is rated as an Advanced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Cellulitis, Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, and Osteomyelitis. Dr. Keshelava is currently accepting new patients.

Advanced in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Mary L. Eschete
Infectious Disease
Advanced in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Mary L. Eschete
Infectious Disease

South Louisiana Medical Associates

1990 Industrial Boulevard, 
Houma, LA 
 (42.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mary Eschete is an Infectious Disease provider in Houma, Louisiana. Dr. Eschete is rated as a Distinguished provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). Her top areas of expertise are Myelitis, HIV/AIDS, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome. Dr. Eschete is currently accepting new patients.

Advanced in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Patrick O. Njoku
Infectious Disease
Advanced in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Patrick O. Njoku
Infectious Disease

Ochsner Clinic LLC

2750 Gause Blvd E, Ochsner Clinic Slidell, 
Slidell, LA 
 (32.8 miles away)
985-639-3777
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Njoku is an Infectious Disease provider in Slidell, Louisiana. Dr. Njoku is rated as a Distinguished provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Osteomyelitis, Osteomyelitis in Children, Cellulitis, and Myelitis. Dr. Njoku is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Garcia-Diaz's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile